Investigating the effect of Q10 in thalassemia patients treated with deferasirox

INTERVENTION: Intervention 1: Intervention group: Receiving 100 mg of Q10 tablets daily for 3 months to thalassemia patients treated with deferasirox. Intervention 2: Control group: Includes patients who receive 100 mg of placebo daily, which does not contain any type of intervention agent, for three months. CONDITION: thalassemia. ; Thalassemia PRIMARY OUTCOME: BUN. Timepoint: At the beginning and end of the third month of using Q10. Method of measurement: Autoanalyzer device. Creatinine. Timepoint: At the beginning and end of the third month of using Q10. Method of measurement: Autoanalyzer device. GFR. Timepoint: At the beginning and end of the third month of using Q10. Method of measurement: Autoanalyzer device. Pr/Cr ratio. Timepoint: At the beginning and end of the third month of using Q10. Method of measurement: Autoanalyzer device. Uric acid. Timepoint: At the beginning and end of the third month of using Q10. Method of measurement: Autoanalyzer device. SECONDARY OUTCOME: Improvement of biochemical parameters of patients. Timepoint: Beginning of study and end of study. Method of measurement: Use of cell counter and autoanalyzer device. Side effects of the studied drugs, especially those such as hypersensitivity reactions, allergies, shock, anemia, hypotension, nausea and vomiting, diarrhea, gastrointestinal spasms, weakness and lethargy, headache, and rash. Timepoint: Side effects are recorded daily in the studied groups. Method of measurement: Examining patients' files and using checklists. INCLUSION CRITERIA: Patients with major and intermedia beta thalassemia disease History of taking Defrasiro Xregularly in the last three months Age between 14 and 40 years